Programs

The Bidan Delima Midwife Training Program seeks to increase the standard of care among Indonesian midwives.

The Boehringer Ingelheim Cares Foundation in the USA provides product donations to assist patients in need worldwide through its partnerships with AmeriCares, Catholic Medical Mission Board, Direct Relief International, MAP International and National Children's Cancer Society. These donations assist in times of disaster, daily struggle or civil conflict around the world and across the USA.

'Delivering Hope' is a comprehensive effort to fight Hepatitis B and C in Asia, sponsored by the Bristol-Myers Squibb Foundation. Delivering Hope has drawn upon the proven models created by the Foundation's work on HIV/AIDS in Africa to address a major health care challenge in resource-constrained settings.

Bristol-Myers Squibb has a long history of partnering with non-profit organizations, donating medical products to support long term health care programs in developing countries as well as addressing immediate needs to provide emergency disaster relief. During the past six years, BMS has donated USD 256 million of medical products, valued at wholesale, to support programs throughout the world. In 2009, BMS product donations totaled over USD 13.2 million. BMS donations have reached more than 125 countries.

Bristol-Myers Squibb's Secure The Future initiative (see HIV/AIDS Capacity Building), in partnership with Baylor College of Medicine, Houston, Texas, USA, funded the first clinical center in Africa for children and families with HIV/AIDS, located in Botswana. This center now has more than 1,500 children under treatment. Additional children's clinical centers have now been opened in Lesotho, Swaziland and Uganda, and two more are being built in Tanzania and Kenya.

The Changing Diabetes in Children program is part of Novo Nordisk's Access to Diabetes Care strategy and aims at improving availability, accessibility, affordability and quality of diabetes care for children with type 1 diabetes in least developed countries, via partnerships. It also contributes to the achievement of the UN Millennium Development Goals, especially Goal 4: Reduce child mortality and Goal 8: Develop a global partnership for development.

The China Diabetes Education Program (CDEP) is a Project HOPE initiative that was launched in 1998. In May 2007, corporate partners Becton Dickinson (BD), Eli Lilly & Company and Roche Diagnostics announced a two-year extension in their support for this program. The CDEP provides comprehensive diabetes training to local medical and healthcare providers - known as "Trained Trainers". To date, Trained Trainers working in 800 local hospitals and community care centers have successfully trained nearly 37,000 medical professionals and educated about 170,000 diabetes patients.

Papua New Guinea has the highest incidence of HIV in the Pacific region. An estimated 2 per cent of the adult population is now HIV positive. Recent research predicts that unless interventions to address the spread and impact are stepped up, by 2025 adult prevalence will have escalated to 11 per cent. Left unchecked, Papua New Guinea will be in a similar position to that of parts of Africa, where the impact of HIV has been felt in every aspect of society and the economy.

Crucell is committed to research and develop innovative vaccines and biologicals, to help developing countries improve their public health and reach the UN Millennium Development Goals. The company is actively involved in private-public partnership R&D initiatives aimed at making available vaccines against malaria, tuberculosis, Ebola and HIV/AIDS to the most needy populations in the world.

In September 2009, Eisai Co., Ltd. and DNDi, a non-profit independent foundation based in Geneva, Switzerland, signed a collaboration and license agreement for the clinical development of Ravuconazole for the treatment of Chagas disease. Ravuconazole, an anti-fungal drug discovered and developed by Eisai, has been shown in in vitro and in vivo to have activity against the pathogen responsible for Chagas disease.

Johnson & Johnson partners with the International Youth Foundation on the HIV/AIDS prevention program Empowering Africa's Young People Initiative in Zambia. Support from Johnson & Johnson enables the International Youth Foundation to expand its services and training, including increasing the number of peer educators who teach other youth in their communities about preventing the spread of HIV/AIDS. Since the partnership began in 2006, more than 1,900 peer educators have been trained.

Sigma-Tau S.p.A. and Medicines for Malaria Venture (MMV) have completed development of Eurartesim a fixed-dose Artemisinin-based Combination Therapy (ACT) which contains dihydroartemisinin (a derivative of artemisinin) and piperaquine. Eurartesim is indicated for the treatment of uncomplicated Plasmodium falciparum malaria. The registration dossier has been submitted to EMA on July 2009. The registration is expected during Q4 2010. After that, dossiers will be submitted to the endemic countries.